Halozyme Earnings Call Highlights Royalty-Fueled Growth

Halozyme Therapeutics ((HALO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Halozyme Therapeutics’ latest earnings call struck a notably upbeat tone, underscoring powerful royalty momentum from ENHANZE-enabled blockbusters and record top-line growth, even as one-off acquisition charges weighed on reported earnings. Management framed 2025 as a pivotal investment year that cements a multi-year growth runway into the 2030s while accepting higher near-term costs and legal overhangs as part of the strategy.

Record Full-Year Revenue Growth

Total revenue for FY2025 climbed 38% year over year to $1.4 billion, marking a record performance powered by the company’s differentiated drug-delivery model. Management emphasized that ENHANZE-driven uptake and expanding product sales are transforming Halozyme from a niche royalty player into a scaled commercial platform.

Royalty Revenue Surge

Royalty revenue surged 52% to $867.8 million, underscoring strong demand for ENHANZE-enabled medicines worldwide. The company highlighted that recurring royalties now represent the core growth engine, providing high-margin, diversified cash flows across multiple partner products.

DARZALEX SC Dominance

The DARZALEX subcutaneous franchise remained the centerpiece, with Johnson & Johnson reporting total DARZALEX sales up 22% operationally to $14.4 billion in 2025. Halozyme booked $483 million in royalties, up 29% year over year, as subcutaneous formulations captured 97% of U.S. sales and are projected to help push DARZALEX above $18 billion by 2028.

PHESGO And VYVGART Hytrulo Break Out

PHESGO sales jumped 48% to roughly $3.0 billion, driving $105.6 million in royalties, a 51% increase that showcases ENHANZE’s value in oncology. Meanwhile, VYVGART and VYVGART Hytrulo revenue soared 90% to $4.15 billion, generating $157.2 million in royalties and an eye-catching 444% growth rate for Halozyme.

Expanded Blockbuster Set Via Approvals

Regulatory momentum was another highlight, with new approvals for DARZALEX FASPRO in smoldering multiple myeloma and an additional newly diagnosed indication, taking DARZALEX to 12 total. RYBREVANT subcutaneous approvals in the U.S., Japan, and China further broadened the franchise, and management now sees 10 ENHANZE-enabled global blockbuster opportunities.

Strategic Acquisitions Broaden Platform

Halozyme used acquisitions to evolve from two to four subcutaneous delivery technologies, adding Elektrofi’s Hypercon platform and Surf Bio’s hyperconcentration technology. These assets, with intellectual property stretching into the mid-2040s, complement ENHANZE and auto-injectors to create a broader, more defensible drug-delivery toolkit.

Hypercon Lays Foundation For 2030s Revenues

The Hypercon platform is still early but central to Halozyme’s long-term story, with three partnerships already secured and two programs slated to enter Phase I by the end of 2026. Management forecast initial approvals around 2030–2031 and envisions Hypercon royalties reaching roughly $1 billion annually within five years of the first launches in the mid-2030s.

ENHANZE Pipeline And New Deals

Pipeline momentum remains robust, with plans to support six new ENHANZE programs entering Phase I in 2026, bringing the total development portfolio to 15 products. The company also expects to sign one to three new ENHANZE agreements, creating visibility to new royalty streams starting near 2029 as today’s development candidates mature.

ADC Data Show Subcutaneous Potential

Preclinical data for two antibody-drug conjugates suggested ENHANZE-enabled subcutaneous dosing could improve injection-site tolerability and pharmacokinetics. The company reported sharp reductions in injection-site volume and peak serum levels versus intravenous dosing, supporting the idea of equal or better exposure with lower peaks that may improve the benefit–risk balance.

Balance Sheet Moves And 2026 Targets

On the financing side, Halozyme issued $1.5 billion in convertible notes due 2031 and 2032, refinanced parts of its 2027 and 2028 notes, and expanded its revolving credit facility to $750 million. Net debt to EBITDA stands at 2.1 times excluding acquired R&D, and management aims to delever to below one time by the end of 2026 while hitting ambitious 2026 revenue and earnings targets.

Quarterly Momentum Into Year-End

Fourth-quarter 2025 results showcased accelerating momentum, with total revenue up 52% sequentially to $451.8 million. Royalty revenue in the quarter climbed 51% year over year to $258 million, reflecting the growing scale and durability of partner product performance.

Acquired IPR&D Charge Weighs On GAAP Results

The Surf Bio acquisition carried a steep $285 million acquired R&D expense in Q4 2025 that heavily impacted reported profitability. That one-time charge cut full-year net income to $316.9 million versus $444.1 million a year earlier and reduced both GAAP and non-GAAP earnings per share by roughly $2.30.

Earnings Pressured Despite Higher EBITDA

GAAP diluted EPS fell to $2.56 from $3.43 in 2024, while non-GAAP diluted EPS edged down to $4.15 from $4.23. Adjusted EBITDA still improved to $657.6 million from $632.2 million, underscoring that core operating performance strengthened even as deal-related accounting masked the underlying earnings power.

Rising Costs Reflect Scale And Legal Spend

Costs moved higher as the company scaled and absorbed transaction-related items, with cost of sales rising to $228.8 million from $159.4 million on greater product volumes. SG&A jumped to $207.1 million from $154.3 million, driven by litigation, consulting and professional fees, acquisition costs, and higher compensation to support a larger enterprise.

Litigation And IP Overhang

Legal and intellectual-property issues remain a notable risk factor, including an inter partes review effort against Alteogen and an infringement case involving Merck that awaits district court scheduling. Management acknowledged these disputes add regulatory and commercial uncertainty, alongside the potential for elevated legal expenses over the coming years.

Seasonal Revenue Cadence And Milestones

Investors were cautioned about near-term lumpiness, with Q1 2026 royalty revenue expected to run about 5%–10% below Q4 2025 due to annual contractual rate resets. Total revenue is also projected to dip sequentially into Q1 because no milestones are planned for that quarter, with milestone contributions weighted toward the second half of the year.

Non-Cash Amortization Climb

Amortization of intangibles increased to $76.7 million from $71.0 million, reflecting the recent acquisition activity and resulting non-cash charges. Management framed this as an expected byproduct of building out a deeper technology portfolio, with limited impact on the company’s strong cash generation.

Forward-Looking Guidance And Strategic Roadmap

Halozyme reiterated 2026 guidance calling for total revenue between $1.71 billion and $1.81 billion and royalty revenue of $1.13 billion to $1.17 billion, implying another year of double-digit growth. The company targets adjusted EBITDA of $1.125 billion to $1.205 billion and non-GAAP EPS of $7.75 to $8.25, while advancing six new ENHANZE and two Hypercon Phase I programs, signing multiple new deals, and driving leverage below one time by late 2026.

Halozyme’s earnings call painted the picture of a company trading near-term earnings dilution for long-term royalty expansion and platform breadth. With blockbuster partners scaling rapidly, new technologies entering the fold, and detailed guidance out to 2026 and beyond, the story centers on durable, high-margin growth tempered by acquisition, legal, and timing-related bumps that investors will need to monitor.